| Abstract | During a post-marketing surveillance study, 641 patients (age range 18 to 86 years) with painful rheumatic diseases, mostly of vertebral etiology, were given ready-for-use infusions containing a combination of the non-steroid antiphlogistic agent diclofenac (75 mg) and the muscle relaxing agent orphenadrine (30 mg) parenterally for 7 days. The goal of the study was to investigate efficacy, tolerability, and acceptance of this intravenous therapy in wide use in physicians' practices. At the end of treatment, the global evaluation resulted in a score of 1.6 on a scale of 1 (very good) to 4 (insufficient). The tolerability score was 1.3 and the acceptability score was 1.5. Only 20 patients (3.1%) had adverse effects, most of which were of gastrointestinal nature. The medication proved appropriate for use in the treatment of painful spine syndromes, inflammatory osteoarthritis, painful osteoporosis, post-operative conditions, and extra-articular rheumatism and could represent a first step towards multi-factorial therapeutic management of these diseases. |
| Authors | F Aglas, F M Fruhwald, K Chlud
(Affiliation: Medizinischen Universitätsklinik Graz.)
|
| Journal | Acta medica Austriaca
(Acta Med Austriaca)
Vol. 25
Issue 3
Pg. 86-90
( 1998)
ISSN: 0303-8173 AUSTRIA |
| Vernacular Title | Ergebnisse einer Anwendungsbeobachtung mit Diclofenac/Orphenadrin-Infusionen bei Patienten mit muskuloskelettalen Krankheiten und Funktionsstörungen. |
| PMID | 9816400
(Publication Type: English Abstract, Journal Article)
|
| Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Muscle Relaxants, Central
- Diclofenac
- Orphenadrine
|
| Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Anti-Inflammatory Agents, Non-Steroidal
(administration & dosage, adverse effects)
- Diclofenac
(administration & dosage, adverse effects)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Humans
- Infusions, Intravenous
- Male
- Middle Aged
- Muscle Relaxants, Central
(administration & dosage, adverse effects)
- Orphenadrine
(administration & dosage, adverse effects)
- Pain Measurement
- Practice Guidelines as Topic
- Product Surveillance, Postmarketing
- Rheumatic Diseases
(drug therapy)
|
